North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial. The company says that it will drop pulmonary drug development altogether in order to focus on its opthalmic products. Read the company’s press release.
Inspire drops respiratory drug program after failure of CF drug
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
